Fundraising FoxIngenia Therapeutics
Cambridge, US · Founded 2018 · Delaware corporation
Find your way into Ingenia Therapeutics
Sign up to see every warm intro you have to Ingenia Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ingenia Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MK
Minji KimExecutiveMinji Kim is a University of Massachusetts Amherst graduate and an executive officer and director at Ingenia Therapeutics, a company focused on research and development.
SH
Sangyeul HanCEOSangyeul Han has research and management experience in therapeutic antibody development, with expertise spanning cancer biology, vascular biology, and inflammation. He has authored over 20 research papers and holds multiple patents in antibody engineering and humanization.
Reported raises · per SEC filings
Form D private placements$16.8M disclosed across 4 rounds · 2019–2024
▶$5MraisedJun 2024 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedJun 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sang Gyun KimDirector
- Eric FurfineDirector
- Joo Hee KwakDirector
- Sangyeul HanExecutive Officer, Director
- Kwang Ho CheongDirector
- Offering amount
- $25M
- Amount sold
- $5M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedNov 2022 · 5 investors · BiotechnologyRule 506(b)
▶$7MraisedNov 2022 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sung Jae KimDirector
- Sangyeul HanExecutive Officer, Director
- Eric FurfineDirector
- Heewon ParkDirector
- Offering amount
- $16M
- Amount sold
- $7M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$4.7MraisedSep 2020 · 9 investors · BiotechnologyRule 506(b)
▶$4.7MraisedSep 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Minji KimExecutive Officer, Director
- Sangyeul HanExecutive Officer, Director
- Offering amount
- $5.7M
- Amount sold
- $4.7M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$100KraisedDec 2019 · 1 investors · Other Health CareRule 506(b)
▶$100KraisedDec 2019 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Minji KimDirector
- Sangyeul HanExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $100K
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Ingenia Therapeutics raised?
- Ingenia Therapeutics has disclosed $16.8M raised across 4 rounds.
- Where is Ingenia Therapeutics headquartered?
- Ingenia Therapeutics is headquartered in Cambridge, US.